Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vor Biopharma Inc. - Common Stock (NQ:VOR)

7.820 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,377
Open 7.820
Bid (Size) 8.000 (300)
Ask (Size) 8.010 (100)
Prev. Close 7.820
Today's Range 7.820 - 7.820
52wk Range 2.622 - 65.80
Shares Outstanding 66,956,800
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Vor Biopharma
Via GlobeNewswire
News headline image
Top movers analysis one hour before the close of the markets on 2025-11-11: top gainers and losers in today's session. ↗
Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill

Performance

YTD
-65.1%
-65.1%
1 Month
-73.4%
-73.4%
3 Month
-82.2%
-82.2%
6 Month
+114.0%
+114.0%
1 Year
-48.9%
-48.9%

More News

Read More
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
News headline image
Dow Gains More Than 300 Points; Energy Vault Holdings Shares Jump ↗
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial ↗
Via Benzinga
News headline image
US Stocks Mixed; Sea Shares Gain After Q3 Results ↗
Via Benzinga
News headline image
Get insights into the top gainers and losers of Tuesday's pre-market session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
Why Rocket Lab Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock
From Vor Biopharma
Via GlobeNewswire
News headline image
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock
From Vor Biopharma
Via GlobeNewswire
News headline image
Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio to Participate in Upcoming Investor Conferences
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical Officer
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vor Biopharma
Via GlobeNewswire
News headline image
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025
From Vor Biopharma
Via GlobeNewswire
News headline image
Novartis Strengthens Kidney Disease Pipeline With Promising Data ↗
Via Benzinga
News headline image
Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine
From Vor Biopharma
Via GlobeNewswire
News headline image
Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears ↗
Via Benzinga

Frequently Asked Questions

Is Vor Biopharma Inc. - Common Stock publicly traded?
Yes, Vor Biopharma Inc. - Common Stock is publicly traded.
What exchange does Vor Biopharma Inc. - Common Stock trade on?
Vor Biopharma Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Vor Biopharma Inc. - Common Stock?
The ticker symbol for Vor Biopharma Inc. - Common Stock is VOR on the Nasdaq Stock Market
What is the current price of Vor Biopharma Inc. - Common Stock?
The current price of Vor Biopharma Inc. - Common Stock is 7.820
When was Vor Biopharma Inc. - Common Stock last traded?
The last trade of Vor Biopharma Inc. - Common Stock was at 11/19/25 04:00 PM ET
What is the market capitalization of Vor Biopharma Inc. - Common Stock?
The market capitalization of Vor Biopharma Inc. - Common Stock is 523.60M
How many shares of Vor Biopharma Inc. - Common Stock are outstanding?
Vor Biopharma Inc. - Common Stock has 524M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.